Dr. Reddy's Laboratories quarterly results

Q2 FY27 · Jul–Sep 2026

₹ crore	Q2 FY27	Q2 FY26	Change
Revenue	8,698	8,828	−1.5%
EBITDA	1,731	2,010	−13.9%
EBITDA margin	19.9%	22.8%	−2.9 pts
Profit before tax	1,235	1,739	−28.9%
Net profit	913	1,337	−31.7%
EPS	₹11.10	₹16.18	−31.4%

Every quarter

₹ crore except per share

Tap a line for its trend	Q2 FY27Sep 2026	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Earlier quartersAlpha Plus

Expenses
	8,698	8,100	7,546	8,753	8,828	8,572	8,528	8,381	8,038	7,696	7,114	7,237	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	156	355	475	269	324	290	522	150	308	187	198	216
	8,854	8,455	8,022	9,022	9,152	8,862	9,051	8,531	8,346	7,883	7,311	7,453
	1,661	1,654	1,199	1,826	1,441	2,036	1,717	1,453	1,287	1,227	1,096	1,141
	1,538	1,974	1,658	1,542	1,746	1,216	1,128	1,051	1,283	1,380	1,176	1,208
	−30.4	−243	356	−272	−63.5	−444	6.0	78.2	−203	−426	−180	−174
	1,612	1,652	1,447	1,589	1,452	1,504	1,401	1,367	1,399	1,414	1,284	1,276
	125	126	106	94.4	90.7	83.0	65.6	81.7	75.7	59.8	59.3	39.4
	527	537	557	521	505	476	455	471	397	381	368	374
	2,187	2,203	2,504	2,182	2,243	2,088	2,280	2,160	2,196	1,971	1,907	1,761
	7,619	7,902	7,827	7,481	7,414	6,958	7,051	6,661	6,434	6,007	5,710	5,627
	1,731	860	383	1,888	2,010	2,174	1,998	2,273	2,077	2,130	1,831	2,023
	1,204	323	−175	1,367	1,505	1,698	1,543	1,802	1,680	1,749	1,464	1,650
Profit
	1,235	553	195	1,541	1,739	1,905	2,000	1,870	1,911	1,877	1,602	1,826
	1,235	553	195	1,541	1,739	1,905	2,000	1,870	1,911	1,877	1,602	1,826
	305	158	−23.7	207	185	1,026	432	533	771	522	282	354
	9.2	−39.8	2.1	146	223	−531	−13.8	−62.9	−196	−31.3	13.1	94.4
	314	118	−21.6	354	408	495	419	470	576	490	295	448
	−7.7	0.8	4.6	2.3	6.3	0.2	5.5	4.2	6.1	5.9	3.5	2.7
	913	436	221	1,190	1,337	1,410	1,587	1,404	1,342	1,392	1,310	1,381
	921	435	217	1,187	1,331	1,410	1,581	1,400	1,336	1,387	1,306	1,378
	3.9	155	246	177	112	205	109	−202	296	1.8	−55.7	99.2
	917	591	467	1,367	1,449	1,615	1,696	1,202	1,638	1,394	1,254	1,480
	925	444	221	1,210	1,347	1,418	1,593	1,414	1,256	—	—	1,381
	−11.6	−8.7	0.4	−20.3	−10.3	−8.2	−6.6	−9.5	86.2	—	0.0	0.0
Per share
	₹11.10	₹5.33	₹2.65	₹14.53	₹16.18	₹17.04	₹19.12	₹16.97	₹15.08	₹83.61	₹78.66	₹82.94
	₹11.09	₹5.33	₹2.65	₹14.52	₹16.17	₹17.02	₹19.10	₹16.94	₹15.05	₹83.48	₹78.53	₹82.81
Other comprehensive income — detail
	3.9	155	246	177	112	205	109	—	—	—	—	—
	−1.3	−0.7	16.8	−1.6	−1.4	0.5	−11.7	−5.2	−3.3	−9.1	−4.4	13.2
	0.0	−0.2	5.6	0.0	0.0	0.0	−2.4	—	—	—	—	—
	—	—	—	—	—	—	—	0.0	0.0	0.0	−0.4	0.0
	0.0	189	217	181	86.2	208	143	−214	298	11.5	−56.5	78.2
	−5.2	33.3	−17.9	2.4	−27.0	3.3	23.8	—	—	—	—	—
	—	—	—	—	—	—	—	−17.0	−1.6	0.6	−4.8	−7.8
	929	599	467	1,387	1,459	1,623	1,703	1,211	1,552	1,394	1,254	1,480
	−11.6	−8.7	0.4	−20.3	−10.3	−8.2	−6.6	−9.5	86.2	0.0	0.0	0.0
Per share — as-filed variants
	₹11.10	₹5.33	₹2.65	₹14.53	₹16.18	₹17.04	₹19.12	₹16.97	₹15.08	₹83.61	₹78.66	₹82.94
	₹11.09	₹5.33	₹2.65	₹14.52	₹16.17	₹17.02	₹19.10	₹16.94	₹15.05	₹83.48	₹78.53	₹82.81
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	5,530	4,715	4,334	5,658	5,705	5,765	5,678	5,800	5,672	5,514	5,022	5,061
	63.6%	58.2%	57.4%	64.6%	64.6%	67.2%	66.6%	69.2%	70.6%	71.7%	70.6%	69.9%
Adjusted (ex-exceptional items) — derived
	1,235	553	195	1,541	1,739	1,905	2,000	1,870	1,911	1,877	1,602	1,826
	913	436	221	1,190	1,337	1,410	1,587	1,404	1,342	1,392	1,310	1,381
	₹11.10	₹5.33	₹2.65	₹14.53	₹16.18	₹17.04	₹19.12	₹16.97	₹15.08	₹83.61	₹78.66	₹82.94

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

DRREDDY₹1,335.40

Dr. Reddy's Laboratories Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersSUNPHARMA CIPLA LUPIN APOLLOHOSP MAXHEALTH DIVISLAB TORNTPHARM ZYDUSLIFEMcap ₹1.12L Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026	Q2 FY27 30/09/2026
Revenue from Operations	7,236.8	7,113.8	7,696.1	8,038.2	8,381.2	8,528.4	8,572.1	8,828.3	8,753.4	7,546.4	8,099.8	8,697.8
Other Income	216.2	197.5	187.2	307.5	150.2	522.1	290.3	323.9	268.8	475.4	354.7	156.2
Total Income	7,453.0	7,311.3	7,883.3	8,345.7	8,531.4	9,050.5	8,862.4	9,152.2	9,022.2	8,021.8	8,454.5	8,854.0
Expenses
+ Cost of Materials Consumed	1,141.2	1,096.2	1,227.2	1,287.2	1,452.6	1,716.5	2,035.8	1,441.3	1,825.5	1,198.6	1,653.8	1,661.0
+ Purchases of Stock-in-Trade	1,208.3	1,175.9	1,380.1	1,282.8	1,050.7	1,127.5	1,215.9	1,745.9	1,542.1	1,657.7	1,973.8	1,537.5
+ Changes in Inventories	-173.5	-180.0	-425.6	-203.3	78.2	6.0	-444.2	-63.5	-272.3	356.4	-242.5	-30.4
+ Employee Benefit Expense	1,276.4	1,283.6	1,413.7	1,399.2	1,366.5	1,400.6	1,503.5	1,452.1	1,588.5	1,446.8	1,651.6	1,611.9
+ Finance Costs	39.4	59.3	59.8	75.7	81.7	65.6	83.0	90.7	94.4	105.7	125.5	124.8
+ Depreciation & Amortisation	373.5	367.7	380.6	397.0	471.4	454.7	476.1	504.6	521.0	557.1	536.6	526.7
+ Other Expenses	1,761.3	1,906.9	1,970.8	2,195.8	2,160.2	2,279.9	2,087.5	2,242.6	2,182.1	2,504.4	2,203.2	2,187.2
Total Expenses	5,626.6	5,709.6	6,006.6	6,434.4	6,661.3	7,050.8	6,957.6	7,413.7	7,481.3	7,826.7	7,902.0	7,618.7
EBITDA	2,023.1	1,831.2	2,129.9	2,076.5	2,273.0	1,997.9	2,173.6	2,009.9	1,887.5	382.5	859.9	1,730.6
EBIT	1,649.6	1,463.5	1,749.3	1,679.5	1,801.6	1,543.2	1,697.5	1,505.3	1,366.5	-174.6	323.3	1,203.9
Profit
PBT before Exceptional Items	1,826.4	1,601.7	1,876.7	1,911.3	1,870.1	1,999.7	1,904.8	1,738.5	1,540.9	195.1	552.5	1,235.3
Pretax Income	1,826.4	1,601.7	1,876.7	1,911.3	1,870.1	1,999.7	1,904.8	1,738.5	1,540.9	195.1	552.5	1,235.3
+ Current Tax	353.8	282.3	521.5	771.3	533.0	432.3	1,026.1	184.7	207.4	-23.7	157.5	305.2
+ Deferred Tax	94.4	13.1	-31.3	-195.8	-62.9	-13.8	-531.0	223.3	146.2	2.1	-39.8	9.2
Tax Expense	448.2	295.4	490.2	575.5	470.1	418.5	495.1	408.0	353.6	-21.6	117.7	314.4
+ Share of Associates & JVs	2.7	3.5	5.9	6.1	4.2	5.5	0.2	6.3	2.3	4.6	0.8	-7.7
Net Income	1,380.9	1,309.8	1,392.4	1,341.9	1,404.2	1,586.7	1,409.9	1,336.8	1,189.6	221.3	435.6	913.2
+ Net Income — Continuing Ops	1,378.2	1,306.3	1,386.5	1,335.8	1,400.0	1,581.2	1,409.7	1,330.5	1,187.3	216.7	434.8	920.9
+ Other Comprehensive Income	99.2	-55.7	1.8	296.1	-202.4	109.4	204.9	111.8	177.0	245.8	155.0	3.9
Total Comprehensive Income	1,480.1	1,254.1	1,394.2	1,638.0	1,201.8	1,696.1	1,614.8	1,448.6	1,366.6	467.1	590.6	917.1
Net Income to Common	1,380.9	—	—	1,255.7	1,413.7	1,593.3	1,418.1	1,347.1	1,209.9	220.9	444.3	924.8
Minority Interest	0.0	0.0	—	86.2	-9.5	-6.6	-8.2	-10.3	-20.3	0.4	-8.7	-11.6
Per Share
Basic EPS	82.94	78.66	83.61	15.08	16.97	19.12	17.04	16.18	14.53	2.65	5.33	11.10
Diluted EPS	82.81	78.53	83.48	15.05	16.94	19.10	17.02	16.17	14.52	2.65	5.33	11.09
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	109.4	204.9	111.8	177.0	245.8	155.0	3.9
+ Items NOT to be Reclassified to P&L	13.2	-4.4	-9.1	-3.3	-5.2	-11.7	0.5	-1.4	-1.6	16.8	-0.7	-1.3
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	-2.4	0.0	0.0	0.0	5.6	-0.2	0.0
+ Tax on Items NOT to be Reclassified — alt tag	0.0	-0.4	0.0	0.0	0.0	—	—	—	—	—	—	—
+ Items to be Reclassified to P&L	78.2	-56.5	11.5	297.8	-214.2	142.5	207.7	86.2	181.0	216.7	188.8	0.0
+ Tax on Items to be Reclassified	—	—	—	—	—	23.8	3.3	-27.0	2.4	-17.9	33.3	-5.2
+ Tax on Items to be Reclassified — alt tag	-7.8	-4.8	0.6	-1.6	-17.0	—	—	—	—	—	—	—
Comprehensive Income — Owners of Parent	1,480.1	1,254.1	1,394.2	1,551.8	1,211.3	1,702.7	1,623.0	1,458.9	1,386.9	466.7	599.3	928.7
Comprehensive Income — Non-controlling Interests	0.0	0.0	0.0	86.2	-9.5	-6.6	-8.2	-10.3	-20.3	0.4	-8.7	-11.6
Per Share — as-filed variants
Basic EPS — Continuing Operations	82.94	78.66	83.61	15.08	16.97	19.12	17.04	16.18	14.53	2.65	5.33	11.10
Diluted EPS — Continuing Operations	82.81	78.53	83.48	15.05	16.94	19.10	17.02	16.17	14.52	2.65	5.33	11.09
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	5,060.8	5,021.7	5,514.4	5,671.5	5,799.7	5,678.4	5,764.6	5,704.6	5,658.1	4,333.7	4,714.7	5,529.7
Gross Margin %	69.93	70.59	71.65	70.56	69.20	66.58	67.25	64.62	64.64	57.43	58.21	63.58
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	1,826.4	1,601.7	1,876.7	1,911.3	1,870.1	1,999.7	1,904.8	1,738.5	1,540.9	195.1	552.5	1,235.3
Net Income Adj (tax-effected)	1,380.9	1,309.8	1,392.4	1,341.9	1,404.2	1,586.7	1,409.9	1,336.8	1,189.6	221.3	435.6	913.2
EPS Adj	82.94	78.66	83.61	15.08	16.97	19.12	17.04	16.18	14.53	2.65	5.33	11.10
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	5.00	—	5.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Paid Up Equity Capital	83.4	83.4	83.4	83.4	83.4	83.4	83.5	83.5	83.5	83.5	83.5	83.5

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q2 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Dr Reddy's Q2 FY27 results (July–September 2026)

Filed with NSE on Friday, 23 October 2026 at 5:29 pm IST

Dr. Reddy's Laboratories (NSE: DRREDDY) reported its Q2 FY27 results (July–September 2026) on Friday, 23 October 2026 at 5:29 pm IST. Consolidated net profit attributable to shareholders was ₹925 crore, down 31.3% from ₹1,347 crore in Q2 FY26 and up 108.1% from ₹444 crore in Q1 FY27. Revenue from operations was ₹8,698 crore, down 1.5% year on year and up 7.4% from the previous quarter.

Q2 FY26 results (a year earlier): 24 October 2025
Q3 FY27 results due by: 14 February 2027

Q2 FY27 at a glance · consolidated

Net profit (shareholders'): ₹925 Cr−31.3% vs Q2 FY26+108.1% vs Q1 FY27Total incl. minority interest ₹913 Cr
Revenue from operations: ₹8,698 Cr−1.5% vs Q2 FY26+7.4% vs Q1 FY27
Operating margin (EBIT): 13.8%−3.2 pts vs Q2 FY26+9.8 pts vs Q1 FY27EBIT ₹1,204 Cr
EBITDA: ₹1,731 Cr−13.9% vs Q2 FY26+101.3% vs Q1 FY27margin 19.9%
Earnings per share (basic): ₹11.10−31.4% vs Q2 FY26+108.3% vs Q1 FY27
Net profit margin: 10.6%−4.6 pts vs Q2 FY26+5.1 pts vs Q1 FY27

Questions

What was Dr Reddy's net profit in Q2 FY27?

Consolidated net profit attributable to shareholders was ₹925 crore, down 31.3% from ₹1,347 crore in Q2 FY26 and up 108.1% from ₹444 crore in Q1 FY27. Including the minority shareholders' share, total profit was ₹913 crore.

How were Dr Reddy's Q2 FY27 results?

Both fell from a year earlier: net profit was down 31.3% at ₹925 crore and revenue was down 1.5% at ₹8,698 crore. The operating margin was 13.8%, down 3.2 percentage points from 17.1% a year earlier. Against Q1 FY27, net profit was up 108.1% and revenue up 7.4%.

What was Dr Reddy's net profit in FY26?

Consolidated net profit attributable to shareholders was ₹4,196 crore in FY26 (April 2025–March 2026), down 25.8% from ₹5,655 crore in FY25. It was ₹5,578 crore in FY24 and ₹4,507 crore in FY23: down 6.9% over three years, an average fall of 2.4% a year.

What was Dr Reddy's revenue in Q2 FY27?

Revenue from operations was ₹8,698 crore, down 1.5% year on year and up 7.4% from the previous quarter.

What was Dr Reddy's EPS in Q2 FY27?

Basic earnings per share were ₹11.10, against ₹16.18 in Q2 FY26.

What is Dr Reddy's net profit margin?

Dr Reddy's net profit margin was 10.6% in Q2 FY27 (net profit attributable to shareholders as a share of revenue from operations), against 15.3% in Q2 FY26 (down 4.6 percentage points). For FY26 as a whole it was 12.5%.

What was Dr Reddy's operating margin in Q2 FY27?

Operating profit (EBIT — revenue less operating expenses, before finance costs and other income) was ₹1,204 crore, a margin of 13.8%, against 4.0% in Q1 FY27 and 17.1% in Q2 FY26. EBITDA was ₹1,731 crore, 19.9% of revenue.

What was Dr Reddy's net profit in the first half of FY27?

Consolidated net profit attributable to shareholders for the first half of FY27 (April–September 2026) was ₹1,369 crore, down 50.5% from ₹2,765 crore in the same months a year earlier. Revenue from operations was ₹16,798 crore, down 3.5%.

When will Dr Reddy's announce its Q3 FY27 results?

Q3 FY27 covers October–December 2026. Listed companies must publish quarterly results within 45 days of the quarter's end (SEBI listing rules, Regulation 33), so the results are due by 14 February 2027. The company tells the exchanges the date of the board meeting at least two working days before it.

How has Dr Reddy's profit changed over the last four quarters?

Net profit attributable to shareholders by quarter: ₹1,210 crore in Q3 FY26, ₹221 crore in Q4 FY26, ₹444 crore in Q1 FY27 and ₹925 crore in Q2 FY27. That is ₹2,800 crore over the four quarters, down 51.5% from ₹5,772 crore in the four quarters before. Revenue from operations: ₹8,753 crore, ₹7,546 crore, ₹8,100 crore and ₹8,698 crore.

What was Dr Reddy's revenue in FY26?

Revenue from operations was ₹33,700 crore in FY26 (April 2025–March 2026), up 3.2% from ₹32,644 crore in FY25. It was ₹28,011 crore in FY24 and ₹24,670 crore in FY23: up 36.6% over three years, 11.0% a year on average.

When did Dr Reddy's announce its Q2 FY27 results?

On Friday, 23 October 2026 at 5:29 pm IST, in its results filing to the stock exchanges. A year earlier it reported Q2 FY26 on 24 October 2025.

Where do these Dr Reddy's figures come from?

From Dr. Reddy's Laboratories' own consolidated results filings to NSE, in ₹ crore as filed (Q2 FY27 on 23 October 2026). Growth compares the same consolidated figures a year and a quarter earlier.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.